CamDiab has earned European approval for its fully closed-loop automated insulin delivery (AID) algorithm, marking a major milestone in diabetes technology. The company announced that its algorithm has received CE marking, allowing people with type 1 diabetes to use insulin automation without counting carbohydrates or giving pre-meal insulin boluses.

This means users can rely on the system to manage insulin delivery on its own, using continuous glucose data to make adjustments without requiring constant input.

CamDiab is best known for its CamAPS FX app, which is already used by many people to automate insulin on compatible pumps throughout Europe. The algorithm is FDA-cleared in the U.S., but does not yet operate on a pump in the states. The app works with TecMed insulin pumps and supports multiple continuous glucose monitors (CGMs), including the FreeStyle Libre 3, Libre 3 Plus, and Dexcom G6. We have previously covered CamAPS FX on the podcast, including how the algorithm and app function and what real-world use looks like.

The newly CE-marked fully closed-loop algorithm takes automation a step further. By removing the need for carb counting and pre-meal insulin dosing, the system aims to significantly reduce the daily mental workload of diabetes management. CamDiab plans to begin a pilot launch of the fully closed-loop algorithm early this year, with a broader rollout expected to follow.

The CE mark highlights continued momentum toward fully closed-loop systems that aim to simplify life with type 1 diabetes. What do you think about CamDiab’s move toward fully closed-loop insulin delivery?

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.